1-10 of 10
Kathleen Colson
Close
Sort by
Journal Articles

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts

Omar Nadeem, MD, Clifton C Mo, MD, Jacob P. Laubach, MD, Giada Bianchi, MD, Robert Redd, Peter Barth, Trevor J. Bayliss, MD, Vaishali Sanchorawala, MD, Leyla Shune, MD, Alexandra Distaso, Virginia Dalton, MS, APRN, Adam S Sperling, MD PhD, Laura Amweg, Mary McKenney, NP, Kathleen Colson, BS,BSN,RN, Ella L Millard, Isabella Hou, Alexandra Savell, BS, Kelly Masone, BA, Nikhil C. Munshi, MD, Irene M. Ghobrial, MD, Kenneth Anderson, MD, Paul G. Richardson, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–2.
https://doi.org/10.1182/blood-2020-141549
Published: 2020
Journal Articles

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

Clinical Trials & Observations
Paul G. Richardson, Wanling Xie, Sundar Jagannath, Andrzej Jakubowiak, Sagar Lonial, Noopur S. Raje, Melissa Alsina, Irene M. Ghobrial, Robert L. Schlossman, Nikhil C. Munshi, Amitabha Mazumder, David H. Vesole, Jonathan L. Kaufman, Kathleen Colson, Mary McKenney, Laura E. Lunde, John Feather, Michelle E. Maglio, Diane Warren, Dixil Francis, Teru Hideshima, Robert Knight, Dixie-Lee Esseltine, Constantine S. Mitsiades, Edie Weller, Kenneth C. Anderson
Journal: Blood
Blood (2014) 123 (10): 1461–1469.
https://doi.org/10.1182/blood-2013-07-517276
Published: 2014
Journal Articles

Final Phase I Results of Perifosine In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed or Refractory Multiple Myeloma (MM)

Andrzej J Jakubowiak, MD, PhD, Paul G Richardson, MD, Todd M Zimmerman, MD, Melissa Alsina, MD, Jonathan L. Kaufman, MD, Malathi Kandarpa, PhD, Colleen K. Harvey, Kathleen Colson, RN, BSN, BS, Monica Mitchell, RN, OCN, Teru Hideshima, MD, PhD, Peter Sportelli, Lesa Gardner, RN, Kathy Giusti, MBA, Kenneth C. Anderson, MD
Journal: Blood
Blood (2010) 116 (21): 3064.
https://doi.org/10.1182/blood.V116.21.3064.3064
Published: 2010
Journal Articles

Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up

Paul G Richardson, MD, Sundar Jagannath, MD, Andrzej J Jakubowiak, MD, PhD, Sagar Lonial, MD, Noopur Raje, MD, Melissa Alsina, MD, Irene Ghobrial, MD, Robert L. Schlossman, MD, Amitabha Mazumder, MD, Nikhil C. Munshi, MD, David H. Vesole, MD, PhD, Kathleen Colson, RN, BSN, BS, Mary L McKenney, MSN, Laura E Lunde, BA, John Feather, Teru Hideshima, MD, PhD, Robert D Knight, MD, Dixie-Lee Esseltine, MD, FRCPC, Constantine S. Mitsiades, MD, PhD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2010) 116 (21): 3049.
https://doi.org/10.1182/blood.V116.21.3049.3049
Published: 2010
Journal Articles

Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory Multiple Myeloma with Pharmacodynamic and Pharmacokinetic Analysis

Anuj Mahindra, MD, Paul G Richardson, Parameswaran Hari, MD, Aliyah R. Sohani, MD, Jacob P. Laubach, MD, Jill Burke, NP, Sarah Kaster, Christine Connolly, Linda Rivera, Paulette Jacobs, Ayman Saad, MD, Kathleen Colson, RN, Irene Ghobrial, MD, Robert L. Schlossman, MD, Jennifer Adams, Wendy Makrides, Edie Weller, Nikhil C. Munshi, MD, Kenneth C. Anderson, Noopur Raje, MD
Journal: Blood
Blood (2010) 116 (21): 3051.
https://doi.org/10.1182/blood.V116.21.3051.3051
Published: 2010
Journal Articles

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.

Paul Richardson, MD, Sundar Jagannath, MD, Andrzej Jakubowiak, MD, PhD, Sagar Lonial, MD, Noopur Raje, MD, Melissa Alsina, MD, Irene Ghobrial, MD, Amitabha Mazumder, MD, Nikhil C Munshi, MD, David H Vesole, MD, PhD, Kathleen Colson, RN, BSN, BS, Mary L McKenney, Laura Lunde, BA, Sarah Kennedy, BS, Kara Kosakowski, Constantine Mitsiades, MD, PhD, Teru Hideshima, MD, PhD, Robert D Knight, MD, Dixie-Lee Esseltine, MD, Kenneth C Anderson, MD
Journal: Blood
Blood (2008) 112 (11): 1742.
https://doi.org/10.1182/blood.V112.11.1742.1742
Published: 2008
Journal Articles

Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Results of a Phase II Study.

Paul Richardson, Sundar Jagannath, Noopur Raje, Andrzej Jakubowiak, Sagar Lonial, Irene Ghobrial, Robert Schlossman, Amitabha Mazumder, Nikhil Munshi, Kathleen Colson, Mary McKenney, Melissa Farrell, Laura Lunde, Lawrence Giove, Sarah Kaster, Constantine Mitsiades, Teru Hideshima, Robert Knight, Dixie-Lee Esseltine, Kenneth Anderson
Journal: Blood
Blood (2007) 110 (11): 2714.
https://doi.org/10.1182/blood.V110.11.2714.2714
Published: 2007
Journal Articles

Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma.

Paul G. Richardson, Constantine S. Mitsiades, Kathleen Colson, Eileen Reilly, Laura McBride, Judy Chiao, Linda Sun, Justin L. Ricker, Syed Rizvi, Carol Oerth, Barbara Atkins, Ivy Fearen, Kenneth C. Anderson, David S. Siegel
Journal: Blood
Blood (2007) 110 (11): 1179.
https://doi.org/10.1182/blood.V110.11.1179.1179
Published: 2007
Journal Articles

Phase I Clinical Trial of Oral Administration of the Histone Deacetylase (HDAC) Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Relapsed/Refractory Multiple Myeloma (MM).

Paul Richardson, MD, Robert L. Schlossman, MD, Constantine S. Mitsiades, MD, PhD, Nikhil C. Munshi, MD, Kathleen Colson, Deborah Doss, Mary McKenney, Karen Hande, Svetlana Gorelik, Laura Lunde, Anna Stepanek, Andrea Freeman, Karyn Dinand, Stephen Hayes, Reggie Michelle, Keith Doucet, Diane Warren, Nicholas Mitsiades, MD, PhD, Victoria M. Richon, PhD, Judi Chiao, MD, PhD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2004) 104 (11): 1503.
https://doi.org/10.1182/blood.V104.11.1503.1503
Published: 2004
Journal Articles

Phase II Trial of Single Agent Bortezomib (VELCADE®) in Patients with Previously Untreated Multiple Myeloma (MM).

Paul G. Richardson, Asher Chanan-Khan, Robert L. Schlossman, Nikhil C. Munshi, Patrick Wen, Hannah Briemberg, David Kuter, Anne-Louise Oaklander, Sagar Lonial, Hani Hassoun, Deborah Doss, Kathleen Colson, Mary McKenney, Karen Hande, Alexandra Koryzna, Barbara Stoklas, Laura Lunde, Svetlana Gorelik, Cliona McAlister, Andrea Freeman, Diane Warren, Denise Collins, Dixie Esseltine, Anthony Amato, Kenneth C. Anderson
Journal: Blood
Blood (2004) 104 (11): 336.
https://doi.org/10.1182/blood.V104.11.336.336
Published: 2004